Introduction
Adrenocortical cancer (ACC) is a rare malignant tumor [1] . Pharmacological therapy is based on mitotane administered alone or in association with the EDP regimen (etoposide, doxorubicin, and cisplatin) [1] . However, the prognosis of ACC patients not amenable to surgery still remains poor and newer treatment strategies are needed [2] . Drugs targeting cell cycle could be a relevant new therapeutic approach for patients with advanced ACC [3] .
Cell cycle is controlled by several key proteins, including CDKs (cyclin-dependent kinases), which are the target of recently discovered cell-cycle checkpoint inhibitors [4] . Palbociclib is a CDK4/6-inhibitor that is active against a broad range of tumors and has an acceptable toxicity, being neutropenia being the most relevant side effect [5] . This drug is actually approved in the management of locally advanced or metastatic breast cancer [6] .
In this study, we investigated in vitro the effect of Palbociclib in NCI-H295R ACC cells and human ACC primary cultures.
Methods

Cell line
NCI-H295R cell line was obtained from the American Type Culture Collection (ATCC) and cultured as suggested.
Primary cell cultures
Human ACC primary cells were derived from surgical specimens of ACC patients after obtaining a written informed consent. They were identified by a sequential number, based on the date of surgery. The project was approved by the local Ethical Committee. ACC02 cell culture derived from a steroid-secreting ACC; whereas ACC03, ACC06, and ACC08 cell cultures derived from non-secreting ACC. After surgical removal, cells were enzymatically digested with collagenase and cultured in the same medium of NCI-H295R cells.
Quantitative RT-PCR (qRT-PCR)
Gene expression was evaluated by qRT-PCR (ViiA7, Applied Biosystems), using the SYBR Green as fluorochrome, as described [7] . Primer sequences are shown in Fig.1 (panel A) .
Cell viability assay
ACC cells were treated up to for 4 days with palbociclib (1 nM−1 µM), solubilized in water. Cell viability was determined by 3-(4,5-Dimethyl-2-thiazol)-2,5-diphenyl-2H-tetrazolium bromide (MTT) dye reduction assay [8] .
Absorbance was determined by a spectrophotometer at 540/ 620 nm (GDV).
Cell cycle analysis
Flow cytometric cell cycle analysis was performed as described [9] . Untreated and treated-NCI-H295R cells were fixed, treated with RNase A (12.5 μg/ml), stained with Propidium iodide (40 μg/ml) and analyzed by Flow Cytometry using a MACS Quant Analyzer (Miltenyi Biotec GmbH) for cell cycle status. Data were analyzed using FlowJo (TreeStar).
Western blot
ACC cell lysates were processed as described [8] . The following primary antibodies were used: Rb protein (pRB) (DB Pharmigen; 2.5 µg/mL), CDK4 or CDK6 kinase (Santa Cruz Biotechnologies; both at 1 µg/mL), cyclin D1 (Cell Signalling; 0.1 µg/mL), p107 and p130 (Santa Cruz Biotechnologies, both at 1 µg/mL) and tubulin (Sigma Aldrich; 0.01 µg/mL). The specific signal was visualized and the densitometric analysis was performed using the GelProAnalyzer version 6.0 (MediaCybernetics).
Statistical analysis
Data analysis was conducted using GraphPad Prism 5 software (GraphPad Software). Statistical analysis was carried out using one-way ANOVA and Bonferroni's Multiple Comparison test. A p value < 0.05 was considered as statistically significant.
Results
CDK 4/6 and Rb protein (pRb) expression
The mRNAs encoding for CDK4/6 and pRb were examined in both NCI-H295R cells and ACC primary cultures using qRT-PCR. Differences in the threshold cycle (Ct) value between the β-actin housekeeping gene and CDK4, CDK6 and Rb genes (ΔCt) were calculated, as an index of the amount of mRNA expressed. Both NCI-H295R cells and ACC primary cultures expressed high amount of mRNA encoding CDK4/6. pRb mRNA was highly detected in ACC primary cultures while it was almost undetectable in NCI-H295R cells (Fig. 1a) . CDK4, CDK6, and pRb were then analyzed by Western Blot, showing that both the CDK kinases were equally expressed. The~106 KDa band, corresponding to the predicted molecular weight of pRb, was detected in ACC02, ACC03, and ACC06 primary cells, but it was almost absent in NCI-H295R and ACC08 cells (Fig. 1b) .
Effect of palbociclib on NCI-H295R cells and ACC primary cultures cell viability
The MTT assay revealed that Palbociclib induced a concentration-dependent decrease of cell viability in each cell culture (Fig. 1c) . Furthermore, Palbociclib significantly decreased the expression levels of the cell cycle-related proteins cyclin D1 (34% ± 2.3 and 46% ± 1.1 of reduction, at 48 and 72 h of treatment, respectively, p < 0.001) (Fig. 1d) , consistent with a G0/G1 cell cycle arrest [10] . CDK4/6 expression did not change after treatment both at mRNA and protein level of (data not shown). Interestingly, a~130 kDa band, likely corresponding to the p130/RBL2 Rb-like family protein [11, 12] , was clearly detected in NCI-H295R cells (Fig. 1e) .
Discussion
This study explored for the first time the in vitro activity of the CDK4/6 antagonist Palbociclib in ACC, using the commercially available NCI-H295R cell line and primary cultures derived from ACC patients. It is known that CDK4/6 inhibition by Palbociclib correlates with greater CDK4/6 inhibitor therapeutic activity, whereas the loss of RB1 is linked to CDK inhibitor resistance [4] . Inactivating mutations or homozygous deletions of the RB1 gene were found in 7% of ACC [13, 14] , indicating that a small proportion of ACC may be potentially resistant to CDK4/6 inhibitors. In this study, while NCI-H295R cells and all the primary ACC cells expressed CDK4 and CDK6, pRb protein was found in 3 out of 4 ACC primary cultures. In the ACC08, in fact, only the pRb transcript was clearly detected, suggesting the presence of a mutation in the translational mechanisms of this protein. In addition, both pRb mRNA and protein were hardly detected in NCI-H295R cells.
Palbociclib significantly affected cell viability in a concentration-dependent way in all ACC cells used in this study, although with a different sensitivity. Overall, the IC 50 values obtained were close to the Cmax of about 51 ng/ml measured after one single dose of 125 mg Palbociclib in Cells were treated with palbocilcib and analyzed for cyclin D1 using Western Blot technique. The human α-tubulin was used as internal control. The specific signal was visualized by the ECL-PLUS system. e Analyses of p107/RBL1 and p130/RBL2 expression in NCI-H295R cells. Lysates from NCI-H295R cells were analyzed for p107/RBL1 and p130/RBL2 expression by using Western Blot technique. The human α-tubulin was used as internal control. The specific signal was visualized by the ECL-PLUS system humans [15] , corresponding to 0.11 µM. Flow cytometric analysis revealed that Palbociclib treatment lead to cell accumulation in G0/G1 phase in NCI-H295R cells, combined with a significant decrease of cyclin D1 levels, while CDK4/6 expression was unchanged. These data confirm also in ACC cells that the cell cycle arrest is likely the main mechanism of the cytotoxic effect of Palbociclib [10] .
Interestingly, despite the lack of pRb expression, both NCI-H295R cells and ACC08 primary culture were sensitive to the anti-tumoral effect of Palbociclib. It is well known that pRb is just one of the multiple targets of the CDK4/6/Cyclin D pathway [11] and a Rb-like family including p107/RBL1 and p130/RBL2 proteins (all substrates for CDK/6 inhibitors) was identified [12] . One of these proteins (p130/RBL2) was detected in NCI-H295R cells in this study. A recent study showed that pRb negative human hepatoma cell lines are sensitive to palbociclib due the expression of both p107/RBL1 and p130/RBL2 [16] .
Several molecular targets have been recently identified for novel treatment approaches in the management of ACC, including mTOR [17, 18] , Wnt-beta catenin signaling pathway [13] , receptors for different growth factors and the ACAT1 [2] and CYP17A1 [19] steroidogenic enzymes.
In this study, we provide a preclinical preliminary evidence that CDK4/6 targeting agents could be effective in the ACC treatment, irrespective pRb expression. Palbociclib, whose toxicity profile seems to be advantageous over the EDP regimen [20] , deserves to be further explored as a new therapeutic option in ACC.
